Login Register Cart 0
Generic placeholder image

Current Drug Delivery

Editor-in-Chief

ISSN (Print): 1567-2018
ISSN (Online): 1875-5704

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Recent Developments in Proniosomal Transdermal Drug Delivery: An Overview

Author(s): Vidya Sabale, Manjusha Charde*, Nitin Dumore and Ujwala Mahajan

Volume 20, Issue 6, 2023

Published on: 11 August, 2022

Page: [683 - 693] Pages: 11

DOI: 10.2174/1567201819666220422153059

Price: $65

Abstract

Proniosomes are the stable carriers used for transdermal application as compared to other vesicular delivery systems like niosomes and liposomes. Oral administration of a drug is associated with severe GIT irritation and first-pass metabolism. The vesicular drug delivery system includes the basic concept of niosomes and proniosomes which describes their mechanism of action, structural formation, interactive study with skin, composition, and method of preparation. Gels contain a high aqueous component as compared to ointment and creams, due to which they can dissolve high concentrations of drugs, and thus help the drug to migrate easily through a vehicle, due to which, gels are considered to be superior in terms of use and patient compliance. This review will focus on the up-to-date research developments in the use of proniosomes, which are applicable to various diseases. Proniosomes are prepared mainly by different concentrations of nonionic surfactants, cholesterol, and lecithin by entrapping hydrophobic as well as hydrophilic drugs. In earlier studies, it was found that the non-ionic surfactants and phospholipids provided higher penetration and it has also been found that some phospholipids have the ability to fluidize the lipid bilayers of the stratum corneum and diffuse through it. In the future, proniosomes may gain more importance in the area of melanoma, brain targeting, protein and peptide drug delivery, gene delivery, hematological drug delivery, and also in cosmetics, and nutraceuticals.

Keywords: Proniosomes, non-ionic surfactant, dry niosomes, transdermal drug delivery, gel, Stratum corneum.

« Previous Next »
Graphical Abstract

[1]
Ahad, A.; Al-Jenoobi, F.I.; Al-Mohizea, A.M.; Akhtar, N.; Raish, M.; Aqil, M. Systemic delivery of β-blockers via transdermal route for hypertension. Saudi Pharm. J., 2015, 23(6), 587-602.
[http://dx.doi.org/10.1016/j.jsps.2013.12.019] [PMID: 26702253]
[2]
Rajan, R.; Jose, S.; Mukund, V.P.; Vasudevan, D.T. Transferosomes - A vesicular transdermal delivery system for enhanced drug permeation. J. Adv. Pharm. Technol. Res., 2011, 2(3), 138-143.
[http://dx.doi.org/10.4103/2231-4040.85524] [PMID: 22171309]
[3]
Barry, B.W. Transdermal drug delivery.In: The science of dosage form Design; Aulton, M.E., Ed.; Churchill livingstone, Elsevier: Hungary, 2007, pp. 565-597.
[4]
Verma, D.D.; Verma, S.; Blume, G.; Fahr, A. Liposomes increase skin penetration of entrapped and non-entrapped hydrophilic substances into human skin: a skin penetration and confocal laser scanning microscopy study. Eur. J. Pharm. Biopharm., 2003, 55(3), 271-277.
[http://dx.doi.org/10.1016/S0939-6411(03)00021-3] [PMID: 12754000]
[5]
Yasam, V.R.; Jawahar, N.; Jakki, S.L. Proniosomes: a novel nano vesicular transdermal drug delivery. J. Pharm. Sci. Res, 2013, 5(8), 153-158.
[6]
Singla, S.; Harikumar, S.L.; Aggarwal, G. Proniosomes for penetration enhancement in transdermal system. Int. J. Drug Dev. Res, 2012, 4(2), 1-13.
[7]
Sharma, A.; Sharma, U.S. Liposomes in drug delivery: Progress and limitations. Int. J. Pharm., 1997, 154(2), 123-140.
[http://dx.doi.org/10.1016/S0378-5173(97)00135-X]
[8]
Chen, S.; Hanning, S.; Falconer, J.; Locke, M.; Wen, J. Recent advances in non-ionic surfactant vesicles (niosomes): Fabrication, characterization, pharmaceutical and cosmetic applications. Eur. J. Pharm. Biopharm., 2019, 144, 18-39.
[http://dx.doi.org/10.1016/j.ejpb.2019.08.015] [PMID: 31446046]
[9]
Fernández-García, R.; Lalatsa, A.; Statts, L.; Bolás-Fernández, F.; Paloma, B.M.; Serrano, D.R. Transferosomes as nanocarriers for drugs across the skin: quality by design from lab to industrial scale. Int. J. Pharm., 2019, 118817.
[http://dx.doi.org/10.1016/j.ijpharm.2019.118817] [PMID: 31678520]
[10]
Semalty, A.; Semalty, M.; Rawat, B.S.; Singh, D.; Rawat, M.S.M. Pharmacosomes: the lipid-based new drug delivery system. Expert Opin. Drug Deliv., 2009, 6(6), 599-612.
[http://dx.doi.org/10.1517/17425240902967607] [PMID: 19519287]
[11]
Aburahma, M.H. Bile salts-containing vesicles: promising pharmaceutical carriers for oral delivery of poorly water-soluble drugs and peptide/protein-based therapeutics or vaccines. Drug Deliv., 2016, 23(6), 1847-1867.
[http://dx.doi.org/10.3109/10717544.2014.976892] [PMID: 25390191]
[12]
Ucisik, M.H.; Sleytr, U.B.; Schuster, B. Emulsomes meet S-layer proteins: an emerging targeted drug delivery system. Curr. Pharm. Biotechnol., 2015, 16(4), 392-405.
[http://dx.doi.org/10.2174/138920101604150218112656] [PMID: 25697368]
[13]
Chaw, C.S.; Ahkim, K.Y. Effect of formulation compositions on niosomal preparations. Pharm. Dev. echnol., 2013, 18, 667-72.
[14]
El Maghraby, G.M.; Ahmed, A.A.; Osman, M.A. Penetration enhancers in proniosomes as a new strategy for enhanced transdermal drug delivery. Saudi Pharm. J., 2015, 23(1), 67-74.
[http://dx.doi.org/10.1016/j.jsps.2014.05.001] [PMID: 25685045]
[15]
Frfkjaer, S.; Hjorth, E.; Wfrtis, O. Stability testing of liposomes during storage. In: Liposome technology; Gregoriadis, G., Ed.; CRC Press: Boca Raton (El), 1984, 1, pp. 235-245.
[16]
Ahmad, M.Z.; Mohammed, A.A.; Mokhtar Ibrahim, M. Technology overview and drug delivery application of proniosome. Pharm. Dev. Technol., 2017, 22(3), 302-311.
[http://dx.doi.org/10.3109/10837450.2015.1135344] [PMID: 26794727]
[17]
Janga, K.Y.; Jukanti, R.; Velpula, A.; Sunkavalli, S.; Bandari, S.; Kandadi, P.; Veerareddy, P.R. Bioavailability enhancement of zaleplon via proliposomes: Role of surface charge. Eur. J. Pharm. Biopharm., 2012, 80(2), 347-357.
[http://dx.doi.org/10.1016/j.ejpb.2011.10.010] [PMID: 22041602]
[18]
Song, S.; Tian, B.; Chen, F.; Zhang, W.; Pan, Y.; Zhang, Q.; Yang, X.; Pan, W. Potentials of proniosomes for improving the oral bioavailability of poorly water-soluble drugs. Drug Dev. Ind. Pharm., 2015, 41(1), 51-62.
[http://dx.doi.org/10.3109/03639045.2013.845841] [PMID: 24111828]
[19]
Yasam, V.R.; Jakki, S.L.; Natarajan, J.; Kuppusamy, G. A review on novel vesicular drug delivery: proniosomes. Drug Deliv., 2014, 21(4), 243-249.
[http://dx.doi.org/10.3109/10717544.2013.841783] [PMID: 24128089]
[20]
Rajera, R.; Nagpal, K.; Singh, S.K.; Mishra, D.N. Niosomes: a controlled and novel drug delivery system. Biol. Pharm. Bull., 2011, 34(7), 945-953.
[http://dx.doi.org/10.1248/bpb.34.945] [PMID: 21719996]
[21]
Singhrawat, A.; Kumar, M.S.; Khurana, B.; Mahadevan, N. Proniosomal gel: a novel topical delivery system. Int. J. A. P. R., 2011, 3, 1-10.
[22]
Vyas, S.P.; Khar, R.K. Niosomes: Targeted and Controlled Drug Delivery, 1st ed.;, 2002, pp. 249-279.
[23]
Sutturwar, P.M.; Fulzele, S.V.; Mande, V.S.; Khandare, J.N. Formulation and evaluation of Ketoconazole Niosomes. Indian J. Pharm., 2002, 64(2), 155-158.
[24]
Ag Seleci, D.; Seleci, M.; Walter, J.G.; Stahl, F.; Scheper, T. Niosomes as nanoparticular drug carriers: fundamental and recent applications. J. Nanomater., 2016, 2016, 1-13.
[http://dx.doi.org/10.1155/2016/7372306]
[25]
Elhissi, A.; Hidayat, K.; Phoenix, D.A.; Mwesigwa, E.; Crean, S.; Ahmed, W.; Faheem, A.; Taylor, K.M. Air-jet and vibrating-mesh nebulization of niosomes generated using a particulate-based proniosome technology. Int. J. Pharm., 2013, 444(1-2), 193-199.
[http://dx.doi.org/10.1016/j.ijpharm.2012.12.040] [PMID: 23299083]
[26]
Blazek-Welsh, A.I.; Rhodes, D.G. Maltodextrin-based proniosomes. AAPS PharmSci, 2001, 3(1), E1.
[http://dx.doi.org/10.1208/ps030101] [PMID: 11741252]
[27]
Ammar, H.O.; Ghorab, M.; El-Nahhas, S.A.; Higazy, I.M. Proniosomes as a carrier system for transdermal delivery of tenoxicam. Int. J. Pharm., 2011, 405(1-2), 142-152.
[http://dx.doi.org/10.1016/j.ijpharm.2010.11.003] [PMID: 21129461]
[28]
Jamal, M.; Imam, S.S.; Aqil, M.; Amir, M.; Mir, S.R.; Mujeeb, M. Transdermal potential and anti-arthritic efficacy of ursolic acid from niosomal gel systems. Int. Immunopharmacol., 2015, 29(2), 361-369.
[http://dx.doi.org/10.1016/j.intimp.2015.10.029] [PMID: 26545446]
[29]
Mokhtar, M.; Sammour, O.A.; Hammad, M.A.; Megrab, N.A. Effect of some formulation parameters on flurbiprofen encapsulation and release rates of niosomes prepared from proniosomes. Int. J. Pharm., 2008, 361(1-2), 104-111.
[http://dx.doi.org/10.1016/j.ijpharm.2008.05.031] [PMID: 18577437]
[30]
Vchegbu, I.F.; Florence, A.T. Non- ionic surfactant vesicles (niosomes): Physical and p’ceutical chemistry. Adv. Colloid Interface Sci., 1995, 58, 1-55.
[http://dx.doi.org/10.1016/0001-8686(95)00242-I]
[31]
Debnath, A.; Kumar, A. Structural and Functional significance of Niosome and Proniosome in Drug Delivery System. Int. J. pharm. Eng, 2015, 3(3), 621-637.
[32]
Yeom, S.; Shin, B.S.; Han, S. An electron spin resonance study of non-ionic surfactant vesicles (niosomes). Chem. Phys. Lipids, 2014, 181, 83-89.
[http://dx.doi.org/10.1016/j.chemphyslip.2014.03.004] [PMID: 24721595]
[33]
Cevc, G. Lipid vesicles and other colloids as drug carriers on the skin. Adv. Drug Deliv. Rev., 2004, 56(5), 675-711.
[http://dx.doi.org/10.1016/j.addr.2003.10.028] [PMID: 15019752]
[34]
Indira, U.; Uma Shankar, M.S. Proniosomes as a Drug Carrier: A Review. Int. J. Pharm. Sci. Res., 2012, 3(12), 4617-4625.
[35]
Aggarwal, D.; Garg, A.; Kaur, I.P. Development of a topical niosomal preparation of acetazolamide: preparation and evaluation. J. Pharm. Pharmacol., 2004, 56(12), 1509-1517.
[http://dx.doi.org/10.1211/0022357044896] [PMID: 15563757]
[36]
Solanki, A.B.; Parikh, J.R.; Parikh, R.H. Formulation and optimization of piroxicam proniosomes by 3-factor, 3-level Box-Behnken design. AAPS PharmSciTech, 2007, 8(4), E86.
[http://dx.doi.org/10.1208/pt0804086] [PMID: 18181547]
[37]
Nairn, J.G. Coacervation-phase separation technology. Adv. Pharm. Sci., 1995, 7, 93-219.
[http://dx.doi.org/10.1016/S0065-3136(06)80005-1]
[38]
Gupta, K.S.; Nappinnai, M.; Gupta, V.R.M. Formulation and evaluation of topical meloxicam niosomal gel. Int. J. Biopharm, 2010, 1, 1-13.
[39]
Youan, B.C.; Hussain, A.; Nguyen, N.T. Evaluation of sucrose esterases alternative surfactants in micro-encapsulation of proteins by the solvent evaporation method. AAPS PharmSciTech, 2003, 5(22)
[40]
Yoshioka, T.; Sternberg, B.; Florence, A.T. Preparation and properties of vesicles (niosomes) of sorbitan monoesters (span 20, 40, 60and 80) and a sorbitan trimester (span 85). Int. J. Pharm., 1994, 105, 1-6.
[http://dx.doi.org/10.1016/0378-5173(94)90228-3]
[41]
Akhilesh, D.; Bini, K.B.; Kamath, J.V. Comparative study of carriers used in proniosomes. Int. J. Pharm. Chem. Sci, 2012, 3, 6-12.
[42]
Zografi, G.; Gennaro, A.R. Interfacial phenomena. Remington: The science and practice of pharmacy, 17th ed; Mark Publishing: Pennsylvania, 1995, pp. 241-251.
[43]
Gannu, P.K.; Pogaku, R. Nonionic surfactant vesicular systems for effective drug delivery—an overview. Acta Pharm. Sin. B, 2011, 1(4), 208-219.
[http://dx.doi.org/10.1016/j.apsb.2011.09.002]
[44]
Ge, X.; Wei, M.; He, S.; Yuan, W.E. Advances of Non- Ionic Surfactant vesicles (Niosomes) and their application in drug delivery. Pharmaceutics, 2019, 11(2), 55.
[http://dx.doi.org/10.3390/pharmaceutics11020055] [PMID: 30700021]
[45]
Bouwstra, J.A.; Van Hal, D.A.; Hofland, H.E.J. Preparation and characterization of nonionic surfactant vesicles. Colloid. Surf. A. Phy. Eng. Asp, 1997, 123-124, 71-80.
[http://dx.doi.org/10.1016/S0927-7757(96)03800-9]
[46]
Manosroi, A.; Wongtrakul, P.; Manosroi, J.; Sakai, H.; Sugawara, F.; Yuasa, M.; Abe, M. Characterization of vesicles prepared with various non-ionic surfactants mixed with cholesterol. Colloids Surf. B Biointerfaces, 2003, 30(1-2), 129-138.
[http://dx.doi.org/10.1016/S0927-7765(03)00080-8]
[47]
Khoee, S.; Yaghoobian, M. Niosomes: A novel approach in modern drug delivery systems. Nanostruct. Drug Deliv., 2017, 207-237.
[48]
Shen, L.; Guo, A.; Zhu, X. Tween surfactants: Adsorption, self-organization, and protein resistance. Surf. Sci., 2011, 605(5-6), 494-499.
[http://dx.doi.org/10.1016/j.susc.2010.12.005]
[49]
Kumari, R.; Varma, K.; Verma, A.; Yadav, K.G.; Maurya, S.D. Proniosomes: A Key to Improved Drug Delivery. J. Drug Deliv. Ther., 2014, 1, 56-63.
[http://dx.doi.org/10.22270/jddt.v0i0.875]
[50]
Debnath, A.; Kumar, A. Structural and Functional significance of Niosome and Proniosome in Drug Delivery System. Inter. J. Pharm. Engin, 2015, 3(3), 621-637.
[51]
Abdelkader, H.; Alani, A.W.; Alany, R.G. Recent advances in non-ionic surfactant vesicles (niosomes): self-assembly, fabrication, characterization, drug delivery applications and limitations. Drug Deliv., 2014, 21(2), 87-100.
[http://dx.doi.org/10.3109/10717544.2013.838077] [PMID: 24156390]
[52]
Yadav, K. Proniosomal Gel: A provesicular approach for transdermal drug delivery. Pharm. Lett., 2010, 2(4), 189-198.
[53]
Varshosaz, J.; Pardakhty, A.; Baharanchi, S.M. Sorbitan monopalmitate-based proniosomes for transdermal delivery of chlorpheniramine maleate. Drug Deliv., 2005, 12(2), 75-82.
[http://dx.doi.org/10.1080/10717540490446044] [PMID: 15824032]
[54]
Khatoon, M.; Shah, K.U.; Din, F.U.; Shah, S.U.; Rehman, A.U.; Dilawar, N.; Khan, A.N. Proniosomes derived niosomes: recent advancements in drug delivery and targeting. Drug Deliv., 2017, 24(sup 1), 56-69.
[http://dx.doi.org/10.1080/10717544.2017.1384520] [PMID: 29130758]
[55]
Gadekar, V.; Bhowmick, M.; Pandey, G.K.; Joshi, A.; Dubey, B. Formulation and evaluation of naproxen proniosomal gel for the treatment of inflammatory and degenerative disorders of the musculo-skeletal system. J. Drug Deliv. Ther., 2013, 3(6), 36-41.
[http://dx.doi.org/10.22270/jddt.v3i6.683]
[56]
Wen, M.M.; Farid, R.M.; Kassem, A.A. Nano-proniosomes enhancing the transdermal delivery of mefenamic acid. J. Liposome Res., 2014, 24(4), 280-289.
[http://dx.doi.org/10.3109/08982104.2014.911313] [PMID: 24779560]
[57]
Ibrahim, M.M.; Shehata, T.M. The enhancement of transdermal permeability of water soluble drug by niosome-emulgel combination. J. Drug Deliv. Sci. Technol., 2012, 22(4), 353-359.
[http://dx.doi.org/10.1016/S1773-2247(12)50059-6]
[58]
Alsarra, I.A.; Bosela, A.A.; Ahmed, S.M.; Mahrous, G.M. Proniosomes as a drug carrier for transdermal delivery of ketorolac. Eur. J. Pharm. Biopharm., 2005, 59(3), 485-490.
[http://dx.doi.org/10.1016/j.ejpb.2004.09.006] [PMID: 15760729]
[59]
Shah, H.; Nair, A.B.; Shah, J.; Bharadia, P.; Al-Dhubiab, B.E. Proniosomal gel for transdermal delivery of lornoxicam: optimization using factorial design and in vivo evaluation in rats. Daru, 2019, 27(1), 59-70.
[http://dx.doi.org/10.1007/s40199-019-00242-x] [PMID: 30701460]
[60]
Soliman, S.M.; Abdelmalak, N.S.; El-Gazayerly, O.N.; Abdelaziz, N. Novel non-ionic surfactant proniosomes for transdermal delivery of lacidipine: optimization using 2(3) factorial design and in vivo evaluation in rabbits. Drug Deliv., 2016, 23(5), 1608-1622.
[http://dx.doi.org/10.3109/10717544.2015.1132797] [PMID: 26758033]
[61]
Thakur, R.; Anwer, M.K.; Shams, M.S.; Ali, A.; Khar, R.K.; Shakeel, F.; Taha, E.I. Proniosomal transdermal therapeutic system of losartan potassium: development and pharmacokinetic evaluation. J. Drug Target., 2009, 17(6), 442-449.
[http://dx.doi.org/10.1080/10611860902963039] [PMID: 19527115]
[62]
Ramkanth, S.; Chetty, C.M.; Sudhakar, Y.; Thiruvengadarajan, V.; Anitha, P.; Gopinath, C. Development, characterization and in vivo evaluation of proniosomal based transdermal delivery system of atenolol. Future J. Pharm. Sci, 2018, 4(1), 80-87.
[http://dx.doi.org/10.1016/j.fjps.2017.10.003]
[63]
Jeevana, J.B.; Guru, L.G. In-vitro and in-vivo evaluation of Transdermal prolonged release proniosomal gel formulations of Propranolol HCL. Int. J. Drug Dev. Res, 2014, 6(3), 7-17.
[64]
Gupta, A.; Prajapati, S.K.; Balamurugan, M.; Singh, M.; Bhatia, D. Design and development of a proniosomal transdermal drug delivery system for captopril. Trop. J. Pharm. Res., 2007, 6(2), 687-693.
[http://dx.doi.org/10.4314/tjpr.v6i2.14647]
[65]
Mateti, A.; Habibuddin, M.; Jukanti, R. Proniosome based transdermal gels of valsartan: Formulation, in-vitro and ex-vivo characteRIZATION. IOSR J. Pharm. Biol. Sci., 2017, 12(5), 67-79.
[66]
Vora, B.; Khopade, A.J.; Jain, N.K. Proniosome based transdermal delivery of levonorgestrel for effective contraception. J. Control. Release, 1998, 54(2), 149-165.
[http://dx.doi.org/10.1016/S0168-3659(97)00100-4] [PMID: 9724902]
[67]
Chauhan, S.B.; Naved, T.; Parvez, N. Formulation development and evaluation of proniosomal gel of ethinylestradiol and levonorgestrel for antifertility treatment. Asian J. Pharm. Clin. Res., 2019, 12(1), 364-368.
[http://dx.doi.org/10.22159/ajpcr.2019.v12i1.29546]
[68]
Loona, S.; Gupta, N.B.; Khan, M.U. Preparation and characterization of metformin proniosomal gel for treatment of diabetes mellitus. Int. J. Pharm. Sci. Rev. Res., 2012, 15(2), 108-114.
[69]
Abdallah, M.H.; Sabry, S.A.; Hasan, A.A. Enhancing Transdermal Delivery of Glimepiride via Entrapment in Proniosomal Gel. J. Young Pharm., 2016, 8(4), 335-340.
[http://dx.doi.org/10.5530/jyp.2016.4.8]
[70]
Prasad, P.S.; Imam, S.S.; Aqil, M.; Sultana, Y.; Ali, A. QbD-based carbopol transgel formulation: characterization, pharmacokinetic assessment and therapeutic efficacy in diabetes. Drug Deliv., 2016, 23(3), 1057-1066.
[http://dx.doi.org/10.3109/10717544.2014.936536] [PMID: 25033041]
[71]
Sagar, S.; Lavanya, S.; Sagar, V.; Nanjwade, B.K. Formulation and evaluation of proniosomal gel of capecitabine. Indo. Am. J. Pharm. Sci, 2017, 4(08), 2513-2520.
[72]
Lather, V.; Sharma, D.; Pandita, D. Proniosomal gel-mediated transdermal delivery of bromocriptine: In vitro and ex vivo evaluation. J. Exp. Nanosci., 2016, 11(13), 1044-1057.
[http://dx.doi.org/10.1080/17458080.2016.1184768]
[73]
Sandeep, G.; Reddy, V.D.; Reddy, S.D. Formulation and evaluation of fluconazole pro-niosomal gel for topical administration. J. Appli. Pharm. Sci., 2014, 4(07), 098-104.
[74]
Benipal, G. Gobindpura; Payal, P.O. Design, development and evaluation of proniosomal gel of an antifungal drug - ketoconazole. Int. J. Pharm. Sci. Rev. Res., 2015, 31(2), 265-272.
[75]
Thomas, L.; Viswanad, V. Formulation and optimization of clotrimazole-loaded proniosomal gel using 3(2) factorial design. Sci. Pharm., 2012, 80(3), 731-748.
[http://dx.doi.org/10.3797/scipharm.1201-03] [PMID: 23008818]
[76]
Rajabalaya, R.; Leen, G.; Chellian, J.; Chakravarthi, S.; David, S.R. Tolterodine tartrate proniosomal gel transdermal delivery for overactive bladder. Pharmaceutics, 2016, 8(3), 27.
[http://dx.doi.org/10.3390/pharmaceutics8030027] [PMID: 27589789]
[77]
Rajabalaya, R.; David, S.R.; Chellian, J.; Xin, Yun G.; Chakravarthi, S. Transdermal delivery of oxybutynin chloride proniosomal gels for the treatment of overactive bladder. Drug Deliv., 2016, 23(5), 1578-1587.
[http://dx.doi.org/10.3109/10717544.2015.1116027] [PMID: 26634274]
[78]
Mateti, A.; Habibuddin, M.; Jadhav, S.; Gandu, S.; Devireddy, S.R. Formulation and evaluation of proniosome based drug delivery system of valcyclovir for in-vitro and ex-vivo performance analysis. J. Glob. Trends Pharm. Sci., 2017, 8(4), 4598-4607.
[79]
Nimbalwar, M.; Upadhye, K.; Dixit, G. Fabrication and evaluation of ritonavir proniosomal transdermal gel as a vesicular drug delivery system. Pharmacophore J., 2016, 7(2), 82-95.
[80]
Rao, M.; Kadam, M.; Rao, S. Formulation and evaluation of topical formulation for cutaneous tuberculosis. J. Drug Deliv. Ther., 2018, 8(4), 102-116.
[http://dx.doi.org/10.22270/jddt.v8i4.1723]
[81]
Fang, J.Y.; Yu, S.Y.; Wu, P.C.; Huang, Y.B.; Tsai, Y.H. in vitro skin permeation of estradiol from various proniosome formulations. Int. J. Pharm., 2001, 215(1-2), 91-99.
[http://dx.doi.org/10.1016/S0378-5173(00)00669-4] [PMID: 11250095]
[82]
Prasad, V.; Chaurasia, S. Performance evaluation of non-ionic surfactant based tazarotene encapsulated proniosomal gel for the treatment of psoriasis. Mater. Sci. Eng. C, 2017, 79, 168-176.
[http://dx.doi.org/10.1016/j.msec.2017.05.036] [PMID: 28629004]
[83]
Shete, A.; Thora, P.; Doijad, R.; Sajane, S. Formulation and in vitro, in vivo evaluation of proniosomal gel of neomycin sulphate. Int. J. App. Pharm, 2019, 11(2), 156-163.
[http://dx.doi.org/10.22159/ijap.2019v11i2.30614]
[84]
Radha, G.V.; Chowdary, C.H.V. Formulation and evaluation of ornidazole proniosomal gel. Indo Ame. J. Pharm. Res., 2014, 4(06)
[85]
El-Laithy, H.M.; Shoukry, O.; Mahran, L.G. Novel sugar esters proniosomes for transdermal delivery of vinpocetine: preclinical and clinical studies. Eur. J. Pharm. Biopharm., 2011, 77(1), 43-55.
[http://dx.doi.org/10.1016/j.ejpb.2010.10.011] [PMID: 21056658]
[86]
Azarbayjani, A.F.; Tan, E.H.; Chan, Y.W.; Chan, S.Y. Transdermal delivery of haloperidol by proniosomal formulations with non-ionic surfactants. Biol. Pharm. Bull., 2009, 32(8), 1453-1458.
[http://dx.doi.org/10.1248/bpb.32.1453] [PMID: 19652389]
[87]
Shah, H.A.; Patel, D.R.; Sonpal, R.N.; Prajapati, P.A.; Patel, M.M. Formulation and comparative evaluation of transdermal patch and proniosomal gel of ropinirole, an anti-Parkinson’s drug. Int. J. Pharm. Sci. Nanotech., 2016, 9(1), 3092-3101.
[88]
Yadav, N.K.; Nanda, S.; Sharma, G.; Katare, O.P. Systematically optimized coenzyme q10-loaded novel proniosomal formulation for treatment of photo-induced aging in mice: characterization, biocompatibility studies, biochemical estimations and anti-aging evaluation. J. Drug Target., 2016, 24(3), 257-271.
[http://dx.doi.org/10.3109/1061186X.2015.1077845] [PMID: 26302815]
[89]
Rahman, S.A.; Abdelmalak, N.S.; Badawi, A.; Elbayoumy, T.; Sabry, N.; El Ramly, A. Formulation of tretinoin-loaded topical proniosomes for treatment of acne: in-vitro characterization, skin irritation test and comparative clinical study. Drug Deliv., 2015, 22(6), 731-739.
[http://dx.doi.org/10.3109/10717544.2014.896428] [PMID: 24670094]
[90]
Sarfaraz, M.D.; Vasantakumar, D.; Doddayya, H.; Goudannavar, P. Use of pronisome gel in antidepressant therapy: Design and evaluation. World J. Pharm. Res., 2014, 3(4), 642-656.
[91]
Thomas, L.; Jose, S.; George, S.J.; Vidya, V. Provesicular niosomes gel: A novel absorption modulator for transdermal delivery. Int. J. Drug Dev. Res, 2011, 3(3), 58-69.

Rights & Permissions Print Cite
Article Metrics
3
© 2024 Bentham Science Publishers | Privacy Policy